Morgan Stanley’s PhenomeX Inc. Common Stock CELL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-37,074
| Closed | -$37K | – | 8059 |
|
|
2023
Q3 | $37K | Sell |
37,074
-395,381
| -91% | -$303K | ﹤0.01% | 6287 |
|
|
2023
Q2 | $212K | Sell |
432,455
-93,187
| -18% | -$76.2K | ﹤0.01% | 5625 |
|
|
2023
Q1 | $610K | Sell |
525,642
-47,872
| -8% | -$87.5K | ﹤0.01% | 5135 |
|
|
2022
Q4 | $1.54M | Sell |
573,514
-962,409
| -63% | -$2.54M | ﹤0.01% | 4620 |
|
|
2022
Q3 | $4.39M | Sell |
1,535,923
-331,831
| -18% | -$1.41M | ﹤0.01% | 3804 |
|
|
2022
Q2 | $9.28M | Sell |
1,867,754
-775,871
| -29% | -$4.06M | ﹤0.01% | 3138 |
|
|
2022
Q1 | $18.8M | Buy |
2,643,625
+1,587,770
| +150% | +$13.1M | ﹤0.01% | 2191 |
|
|
2021
Q4 | $19.2M | Buy |
1,055,855
+58,074
| +6% | +$1.25M | ﹤0.01% | 2202 |
|
|
2021
Q3 | $19.5M | Buy |
997,781
+647,793
| +185% | +$24.6M | ﹤0.01% | 2112 |
|
|
2021
Q2 | $15.7M | Sell |
349,988
-226,975
| -39% | -$10.5M | ﹤0.01% | 2438 |
|
|
2021
Q1 | $29M | Buy |
576,963
+395,195
| +217% | +$26.9M | ﹤0.01% | 1587 |
|
|
2020
Q4 | $16.3M | Sell |
181,768
-182,552
| -50% | -$15.4M | ﹤0.01% | 2019 |
|
|
2020
Q3 | $27.8M | Buy |
+364,320
| New | +$23.1M | 0.01% | 1241 |
|
Morgan Stanley's CELL Position: Q4 2023 in Review
Morgan Stanley sold out of PhenomeX Inc. Common Stock (CELL) in Q4 2023, closing a stake of 37,074 shares — an estimated $37K sold.
Morgan Stanley first reported a position in CELL in Q3 2020 and held it in 13 quarters. The position peaked at $29M in Q1 2021. 0 funds tracked by Wall St. Rank hold CELL as of Q4 2023.
- Morgan Stanley reported no remaining PhenomeX Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
- Morgan Stanley sold 37,074 PhenomeX Inc. Common Stock shares in Q4 2023, an estimated $37K.
- Morgan Stanley first reported a position in PhenomeX Inc. Common Stock in Q3 2020 and held it in 13 quarters.
- Morgan Stanley's PhenomeX Inc. Common Stock position peaked at $29M in Q1 2021.
- 0 funds tracked by Wall St. Rank held PhenomeX Inc. Common Stock as of Q4 2023.
Based on Morgan Stanley's 13F filing for Q4 2023, filed 13 Feb 2024.